PMID- 27196460
OWN - NLM
STAT- MEDLINE
DCOM- 20170217
LR  - 20220408
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 95
IP  - 20
DP  - 2016 May
TI  - Efficacy and Safety of Celecoxib Therapy in Osteoarthritis: A Meta-Analysis of 
      Randomized Controlled Trials.
PG  - e3585
LID - 10.1097/MD.0000000000003585 [doi]
LID - e3585
AB  - Osteoarthritis (OA) is the most common form of arthritis in older individuals and 
      is among the most prevalent and disabling chronic conditions worldwide.We 
      conducted a meta-analysis to determine the efficacy and safety of celecoxib, a 
      cyclooxygenase-2 (COX-2) inhibitor in the treatment of osteoarthritis. Studies 
      were pooled, and mean difference (MD), relative risk (RR), and its corresponding 
      95% confidence interval (CI) were calculated. Fifteen relevant articles were 
      included for this meta-analysis study.We observed that osteoarthritis total score 
      (MD = -4.41, 95% CI -7.27 to -1.55), pain subscale score (MD = -0.86, 95% CI 
      -1.10 to -0.62), and function subscale score (MD = -2.90, 95% CI -5.12 to -0.67) 
      in OA patients treatment with celecoxib was significantly improved than that with 
      placebo. There was no significant difference in the incidence of adverse events 
      (AEs), SAEs, and discontinuations due to AEs; however, the incidence of 
      gastrointestinal AEs in OA patients treatment with celecoxib is significantly 
      higher than that with placebo. For AE, the incidence of abdominal pain in OA 
      patients with celecoxib was significantly higher than that with placebo 
      (RR = 2.24, 95% CI: 1.40-3.58; P = 0.839, I = 0%). There was no significant 
      difference in diarrhea, dyspepsia, headache, and nausea.This meta-analysis 
      indicated that celecoxib treatment (200 mg orally once daily) led to significant 
      improvement in the pain and function of osteoarthritis. However, compared with 
      placebo control, celecoxib resulted in greater gastrointestinal AEs, especially 
      abdominal pain after approximately 10 to 13 weeks of treatment. The current 
      study, therefore, provides valuable information to help physicians make treatment 
      decisions for their patients with OA.
FAU - Xu, Chao
AU  - Xu C
AD  - From the Department of Orthopaedics, the Second Affiliated Hospital of Xinjiang 
      Medical University, Urumchi (CX, YY, YH); and Department of Pain and Minimally 
      Invasive, the 316th Hospital of People's Liberation Army, Beijing (KG), China.
FAU - Gu, Ke
AU  - Gu K
FAU - Yasen, Yalikun
AU  - Yasen Y
FAU - Hou, Yanjie
AU  - Hou Y
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - JCX84Q7J1L (Celecoxib)
SB  - IM
MH  - Abdominal Pain/chemically induced
MH  - Celecoxib/adverse effects/*therapeutic use
MH  - Chronic Pain/*drug therapy/etiology
MH  - Cyclooxygenase 2 Inhibitors/adverse effects/*therapeutic use
MH  - Diarrhea/chemically induced
MH  - Dyspepsia/chemically induced
MH  - Headache/chemically induced
MH  - Nausea/chemically induced
MH  - Osteoarthritis/complications/*drug therapy/physiopathology
MH  - Randomized Controlled Trials as Topic
PMC - PMC4902402
COIS- The authors have no funding and conflicts of interest to disclose.
EDAT- 2016/05/20 06:00
MHDA- 2017/02/18 06:00
PMCR- 2016/05/20
CRDT- 2016/05/20 06:00
PHST- 2016/05/20 06:00 [entrez]
PHST- 2016/05/20 06:00 [pubmed]
PHST- 2017/02/18 06:00 [medline]
PHST- 2016/05/20 00:00 [pmc-release]
AID - 00005792-201605170-00021 [pii]
AID - 10.1097/MD.0000000000003585 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2016 May;95(20):e3585. doi: 10.1097/MD.0000000000003585.